Furthermore, acute CDK4/6 inhibitor treatment reduced the percentage of cells in S/G2 in a variety of normal and cancer cells, suggesting that G1 extension and less efficient cell-cycle entry are general phenomena in CDK4/6-inhibited cells (Fig. 1g). Here, CDK4 is linked to cancer.